LightDark Log in Sign up

‹ Back to screener

TORNTPHARM.NS Torrent Pharmaceuticals Ltd.

Healthcare

Price history

1M 6M 1Y 3Y Max
2021-08-23 ₹1530.95
2026-08-21 ₹4910.50
Change over window +220.75%

Price is the daily close from stored Kite history. The other metrics pair that daily price with the company's periodic filings — each fundamental (revenue, EPS, equity…) is held flat at its latest filed value between annual filings, so a ratio steps at each filing and moves daily only through its price term. A metric with no input on file for this company (e.g. EV/EBITDA for a bank, which has no EBIT) is shown as unavailable, never guessed. Share-count-based metrics use the latest diluted share count against split/bonus-adjusted prices.

Technical indicators

ℹ These reflect only the stock's recent price and volume behavior — not the company's fundamentals — and are not a recommendation to buy or sell. Standard published parameters are used throughout (see each chart's own label); a company with too little stored price history for a given indicator's lookback window shows that plainly below rather than a garbage or misleading value.

MACD (12,26,9), Stochastic Oscillator (14,3) and Money Flow Index (14-day) each carry their own published reference lines/bands (20/80 for the oscillator readings) where one is standard. ADX includes +DI/-DI for direction alongside trend strength; a dashed line marks the commonly published 25 "trending market" reading. ATR is shown in raw rupees here; the price/volume preset screen (below, and on the Screener page) reports it as a % of price so it's comparable across stocks at different price levels. Computed from the same stored daily OHLCV history as the price chart above — no new data source.

Delivery volume

Latest (2026-08-28) 48.8%
Trailing 20-day average 62.4%
Date Traded Qty Delivery Qty Delivery %
2026-08-28 184156 89924 48.83%
2026-08-27 317547 196696 61.94%
2026-08-26 277585 180280 64.95%
2026-08-25 214851 129705 60.37%
2026-08-24 151552 87712 57.88%
2026-08-21 226264 124959 55.23%
2026-08-20 244562 146870 60.05%
2026-08-19 412375 271076 65.74%
2026-08-18 426573 226193 53.03%
2026-08-17 293772 168473 57.35%
2026-08-14 166892 96497 57.82%
2026-08-13 433488 300991 69.43%
2026-08-12 400740 263310 65.71%
2026-08-11 360860 226630 62.80%
2026-08-10 416376 287752 69.11%
2026-08-07 394462 265360 67.27%
2026-08-06 701944 533569 76.01%
2026-08-05 509606 322266 63.24%
2026-08-04 658560 468816 71.19%
2026-08-03 841750 500847 59.50%

Delivery quantity/percentage from the NSE bhavcopy (DELIV_QTY/DELIV_PER) — the share of that day's traded volume that actually settled into a demat account, rather than being squared off intraday. A higher delivery percentage is commonly read as genuine accumulation/distribution rather than speculative same-day trading; this describes recent trading PATTERN, not the company itself, and is not a recommendation to buy or sell. A blank cell is a day NSE itself published no figure for, never a zero. Run python manage.py refresh_delivery_volumes --tickers TORNTPHARM.NS to fetch more history.

Insider trading activity

Disclosed Person Category Type Mode Quantity Value (₹) Resulting stake
29 Nov 2024 Jinesh Shah, Designated Person (in capacity of trustee of Jinesh Trust) Other Buy Gift 930144 0 0.27% XBRL
20 Oct 2021 Shailesh Haribhakti Director Pledge Pledge Creation 3600 10058040 0.00% XBRL
25 Jun 2021 Shailesh Haribhakti Director Buy Market Purchase 6875 19936893 0.00% XBRL
03 Jun 2021 Shailesh Haribhakti Director Buy Market Purchase 1050 2944025 0.00% XBRL
02 Jun 2021 Shailesh Haribhakti Director Buy Market Purchase 1820 5005018 0.00% XBRL
01 Jun 2021 Shailesh Haribhakti Director Buy Market Purchase 730 1997986 0.00% XBRL
07 Jan 2021 Harish Guttikar - Buy Market Purchase 400 1086400 0.00% XBRL
07 Jan 2021 Harish Guttikar - Sell Market Sale 200 555600 0.00% XBRL
03 Oct 2020 Karan Shah Employees/Designated Employees Buy Market Purchase 117 257562 0.00% XBRL
03 Oct 2020 Karan Shah Employees/Designated Employees Sell Market Sale 1085 2313319 0.00% XBRL
03 Oct 2020 Karan Shah Employees/Designated Employees Sell Market Sale 117 257700 0.00% XBRL
03 Oct 2020 Karan Shah Employees/Designated Employees Buy Market Purchase 1085 2329360 0.00% XBRL
27 Feb 2020 Ameera Shah Director Sell Market Sale 1200 2664000 0.00% XBRL
15 Nov 2018 Ameera Shah Director Buy Market Purchase 1200 1993738 0.00% XBRL
29 Dec 2017 Shailesh Haribhakti Director Sell Market Sale 6000 8391600 0.00%
30 Mar 2017 Varun Sudir Mehta Promoters Sell Inter-se-Transfer 1749900 2451609900 0.00%
30 Mar 2017 Jinal Sudhir Mehta Promoters Sell Inter-se-Transfer 1752900 2455812900 0.00%
30 Mar 2017 Anita Sudhir Mehta Promoters Sell Inter-se-Transfer 6120168 8574355368 0.00%
30 Mar 2017 Sudhir Uttamlal Mehta HUF Promoters Sell Inter-se-Transfer 1717380 2406049380 0.00%
30 Mar 2017 Sudhir Uttamlal Mehta Promoters Sell Inter-se-Transfer 5885276 8245271676 0.00%

SEBI PIT (Prohibition of Insider Trading) Regulation 7 disclosures — designated persons (promoters, directors, KMPs, and their immediate relatives) reporting their own dealing in the company's securities, as NSE publishes them. Distinct from the SAST (Regulation 29 substantial-acquisition) filings on the market-wide SAST activity page. Public record only — this is descriptive disclosure data, not a signal, and is not a recommendation to buy or sell. Run python manage.py refresh_insider_trades --tickers TORNTPHARM.NS to fetch more.

Ratios as of FY2025-26 (Annual) · Price ₹4896.50 INR (live) · fetched 2026-08-24 00:34 price stale

Extract this company (financials + ratios + citations): CSV · XLSX

Full statements: Profit & Loss · Balance Sheet · Cash Flow · Compare with 46 peers in Healthcare · Trace Score

Ratios

P/E
76.62
P/E = Price / EPS
Source trace
P/E = Price / (ProfitOrLossAttributableToOwnersOfParent / PaidUpValueOfEquityShareCapital ÷ FaceValueOfEquityShareCapital) → ₹4,896.50 / (₹21,630,000,000 / 338,460,000 shares) = ₹4,896.50 / ₹63.91 EPS
FY2025-26 · Annual filing
ROE
25.78%
ROE = Net Income / Shareholder Equity
Source trace
ROE = ProfitOrLossAttributableToOwnersOfParent / EquityAttributableToOwnersOfParent → ₹21,630,000,000 / ₹83,890,000,000 = 25.78%
FY2025-26 · Annual filing
Debt/Equity
1.76
Debt/Equity = Total Debt / Shareholder Equity
Source trace
Debt/Equity = BorrowingsCurrent + BorrowingsNoncurrent / EquityAttributableToOwnersOfParent → ₹147,980,000,000 / ₹83,890,000,000 = 1.76
FY2025-26 · Annual filing
Current Ratio
1.13
Current Ratio = Current Assets / Current Liabilities
Source trace
Current Ratio = CurrentAssets / CurrentLiabilities → ₹93,920,000,000 / ₹83,430,000,000 = 1.13
FY2025-26 · Annual filing
ROCE
14.43%
ROCE = EBIT / (Shareholder Equity + Total Debt)
Source trace
ROCE = ProfitBeforeExceptionalItemsAndTax + FinanceCosts / (EquityAttributableToOwnersOfParent + BorrowingsCurrent + BorrowingsNoncurrent) → ₹33,460,000,000 / (₹83,890,000,000 + ₹147,980,000,000) = 14.43%
FY2025-26 · Annual filing
Dividend Yield
0.78%
Dividend Yield = (Dividends Paid / Diluted Shares Outstanding) / Price

This is cash paid during the fiscal year, not a per-share rate declared for it (no such element exists in the filing data) — timing can straddle interim/final dividends across years, and pre-FY2020-21 figures may include the since-abolished Dividend Distribution Tax, reading higher than later years for that reason alone.

Source trace
Dividend Yield = (|DividendsPaidClassifiedAsFinancingActivities| / PaidUpValueOfEquityShareCapital ÷ FaceValueOfEquityShareCapital) / Price → (₹12,890,000,000 / 338,460,000 shares) / ₹4,896.50 = ₹38.08 / ₹4,896.50
FY2025-26 · Annual filing

Growth & earnings trend

Revenue & Profit CAGR

Revenue (3y, 3.0y actual) 13.3%
Net Profit (3y) 20.2%
Revenue (5y, 3.0y actual) 13.3%
Net Profit (5y) 20.2%
Revenue (10y, 3.0y actual) 13.3%
Net Profit (10y) 20.2%

Operating Margin Trend

Expanding

FY2022-23 22.7%
FY2023-24 24.4%
FY2024-25 25.6%
FY2025-26 23.9%

ROCE Trajectory

FY2022-23 19.0%
FY2023-24 24.3%
FY2024-25 27.8%
FY2025-26 10.3%

Earnings Quality

No persistent gap detected

Net Profit CAGR 20.21% vs CFO CAGR 8.48% over 3.0y (2023-03-31 → 2026-03-31); most recent year: Net Profit +13.19% vs CFO +16.94%

Sector-Relative Percentile (Healthcare)

ROE 98th
ROCE 39th
Debt/Equity 0th
P/E 26th

Quarterly trend

Revenue Net Profit Net Profit (loss quarter)
Metric (to shareholders basis) Q4 FY2023-24 Q1 FY2024-25 Q2 FY2024-25 Q3 FY2024-25 Q4 FY2024-25 Q1 FY2025-26 Q2 FY2025-26 Q3 FY2025-26 Q4 FY2025-26 Q1 FY2026-27 Source
Revenue ₹2,745.00 Cr. ₹2,859.00 Cr. ₹2,889.00 Cr. ₹2,809.00 Cr. ₹2,959.00 Cr. ₹3,178.00 Cr. ₹3,302.00 Cr. ₹3,303.00 Cr. ₹4,197.00 Cr. ₹4,921.00 Cr. RevenueFromOperations
Net Profit ₹449.00 Cr. ₹457.00 Cr. ₹453.00 Cr. ₹503.00 Cr. ₹498.00 Cr. ₹548.00 Cr. ₹591.00 Cr. ₹635.00 Cr. ₹389.00 Cr. incl. minority ₹364.00 Cr. ₹566.00 Cr. ProfitOrLossAttributableToOwnersOfParent

Primary figures are Revenue from Operations and Net Profit attributable to shareholders — the basis the ratios use. Where they differ, the companion Gross revenue (incl. inter-segment) and incl. minority net profit (the totals a news headline usually quotes) are shown beneath, each traceable to its own XBRL element. Quarters shown are however many are actually stored (up to 10) — run python manage.py refresh_quarterly_trend --tickers TORNTPHARM.NS to fetch more.

Source document — income statement (FY2025-26, raw filing line items)

View original filing on NSE ↗ NSE's own filing document, opened in a new tab — StockProof links to it, never stores a copy.

ProfitOrLossAttributableToOwnersOfParent21630000000.0
PaidUpValueOfEquityShareCapital ÷ FaceValueOfEquityShareCapital338460000.0
Source document — balance sheet (FY2025-26, raw filing line items)

View original filing on NSE ↗ NSE's own filing document, opened in a new tab — StockProof links to it, never stores a copy.

CurrentAssets93920000000.0
CurrentLiabilities83430000000.0
EquityAttributableToOwnersOfParent83890000000.0
BorrowingsCurrent + BorrowingsNoncurrent147980000000.0

My notes